PRAX Stock Discussion
Praxis Precision Medicines, Inc. Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Central Nervous System Disorders Epilepsy Precision Medicine Depression Major Depressive Disorder Nervous System Disorders Depressive Disorder Huntington's Disease Oligonucleotide Treatment Of Major Depressive Disorder Spinal Muscular Atrophy Neuron Antisense RNA Essential Tremor Receptor Positive Ionis Perimenopausal Depression
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles